Une molécule issue d’un champignon comestible pourrait ouvrir des perspectives thérapeutiques pour des patients atteints de mucoviscidose, la maladie génétique rare la plus fréquente. Une équipe de recherche dirigée par Fabrice Lejeune, chercheur Inserm au sein du laboratoire Cancer heterogeneity, plasticity and resistance to Therapies (Inserm/ CNRS/ Université de Lille/Institut Pasteur de Lille/CHU Lille) a testé les effets de la 2,6-diaminopurine (DAP), l’un des principes actifs contenus dans...
Cisplatin is a chemotherapy indicated to fight tumors in many types of cancer. However, it does have major side effects – especially kidney toxicity, that can lead to acute kidney failure. In addition, patients treated with cisplatin also often report high levels of neuropathic pain. Scientists from Inserm, Université de Lille, University Hospital Lille, CNRS and Institut Pasteur de Lille within the CANTHER and Lille Neuroscience & Cognition laboratories,...
In a new study, researchers investigated a receptor found on male germ cells that produce gametes, their aim being to find out more about its role in chemotherapy-related infertility. Their findings pave the way for a better understanding of male infertility and the development of treatments to reduce the risk of sterility from chemotherapy.
In patients with familial adenomatous polyposis, a genetic disease predisposing to colon cancer, mutations of the APC gene induce the formation of intestinal polyps, but also reduce immune system activity. In a new study, researchers describe the mechanisms that modify the structure of T lymphocytes and hinder their migration towards the tumors to be destroyed. This discovery provides new perspectives on the migration of immune cells, a key process...
In order to evaluate the risk of cancer linked to them, researchers analyzed data relating to the health of 102,865 French adults participating in the NutriNet-Santé cohort study and their consumption of artificial sweeteners. The results of these statistical analyses suggest a link between the consumption of artificial sweeteners and an increased risk of cancer.
Annually over 50,000 bone marrow transplantations occur worldwide as a therapy for multiple cancerous and non-cancerous diseases. Yet, how this procedure gives rise to bone marrow-derived cells that engraft the brain, despite being absent in the normal brain, remains unknown. Scientists discovered how the host’s microglia, the brain’s innate immune cells, are replaced by bone marrow-derived macrophages. The key discovery was that transplantation chemotherapy eliminated the microglia’s regenerative capacity,...
Monoclonal antibody therapy can be very effective in treating numerous illnesses, such as cancers, chronic inflammatory conditions, and infectious diseases. Researchers from Inserm, Université de Paris, Sorbonne Université and CNRS1 have designed and tested a new immunotherapy approach that uses pre-existing antibodies directed against the Epstein-Barr virus – part of the herpes family of viruses and present in over 95% of the world's population – in order to target...
Le Paris Saclay Cancer Cluster est désormais organisé sous la forme d’une association, dont l’objet et les ambitions ont été présentés ce jour dans les locaux de Gustave Roussy, en présence d’Olivier Véran, Ministre des Solidarités et de la Santé, de Frédérique Vidal, Ministre de l’Enseignement supérieur, de la Recherche et de l’Innovation et des représentants des cinq membres fondateurs : Sanofi, Gustave Roussy, l’Inserm, l’Institut Polytechnique de Paris...
Immunotherapy, a therapeutic strategy aimed at increasing the activity of the immune system in order to recognize and destroy cancer cells, has revolutionized cancer treatment over the past decade. For the first time, the scientists were able to film the lymphocytes infiltrating the walls of the HEV vessels to enter the tumors. The likelihood of recovery of patients with metastatic melanoma (skin cancer) and treated with immunotherapy is increased...
While the care and treatment of acute myeloid leukemia (AML) have greatly improved in recent years, overall survival remains low. Resistance to the various treatments continues to present a major clinical challenge. Using animal models, and also by working with patients themselves, scientists have identified a new biomarker predictive of response to dual therapy (chemotherapy plus targeted therapy) used in AML, as well as resistance mechanisms behind relapses.
